Tilray Brands, Inc. Common Stock (TLRY) Stock Price
TLRYStock
$3.04−80.26%52W
Market Cap$449.27M
P/E—
PEG Ratio—
Div yield—
Beta2.05
TLRY Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-65.91%
Price vs S&P 500 (4W)-24.17%
VGM Score55.00
TLRY Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q3 2026 | -$0.14 | -$0.02 | +85.71%(+$0.12) | |
| Q2 2026 | $0.21 | $0.05 | -76.19%(-$0.16) | |
| Q1 2026 | $0.07 | $0.02 | -71.43%(-$0.05) | |
| Q4 2025 | $0.00 | -$0.02 | +0.00%(-$0.02) | |
| Q3 2025 | $0.00 | $0.00 | +0.00%(+$0.00) | |
| Q2 2025 | $0.00 | $0.20 | +0.00%(+$0.20) |
TLRY Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.65
3.65
3.65
3.65
Industry Peers — Pharmaceutical Preparations(21)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
TLRYTilray Brands, Inc. Common Stock | B | B | D | 0.5x | 15.9% | 29.1% | — | $3.04 |
| RGCRegencell Bioscience Holdings Limited Ordinary Shares | — | — | B | — | — | — | — | $9.59 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | B | — | — | — | — | $32.10 |
| TRLVTrulieve Cannabis Corp. | B | C | A | 1.7x | -3.9% | 59.5% | — | $10.01 |
| CRONCronos Group Inc. Common Share | C | B | A | 6.6x | 37.5% | 46.5% | -50.0% | $3.21 |
| CGCCanopy Growth Corporation Common Shares | B | C | D | 1.6x | 6.8% | 28.5% | — | $0.71 |
| SNDLSundial Growers Inc. Common Shares | B | C | B | 0.5x | -1.7% | 26.2% | — | $1.25 |
| GLASGlass House Brands Inc. | B | C | D | 1.2x | -25.6% | 30.8% | — | $3.19 |
| USNAUSANA Health Sciences Inc | B | D | C | 0.3x | 5.7% | 77.5% | -37.0% | $15.54 |
| ACBAurora Cannabis Inc. Common Shares | B | D | B | 1.3x | -18.9% | 6.3% | — | $3.99 |
| NAGENiagen Bioscience, Inc. Common Stock | C | C | D | 1.5x | 11.0% | 64.2% | — | $2.49 |
About Tilray Brands, Inc. Common Stock
Tilray is a Canadian cannabis producer cultivating and distributing medical and recreational cannabis products. The company generates revenue primarily from the Canadian market and international medical cannabis exports, with U.S. operations concentrated in alcohol.